EUVIMEDEUVIMED entdecken
Open Access

Evaluation of the Toxicity and Efficacy of an Adeno-Associated Viral Vector Expressing BEST1 Delivered by Subretinal Injection in a Canine Model of Human Bestrophinopathy

Alexa Gray, Jennifer C Kwok, Yu Sato iD, Charles-Antoine Assenmacher, Mayur Choudhary, Ash Jayagopal, Peiying Hua, Gui-Shuang Ying, Malgorzata Swider, Alexander Sumaroka, Artur V Cideciyan, Aguirre D Gustavo und 1 weitere

Human Gene Therapy · 2026

DOI: 10.1177/10430342261458076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2026. Verfasst von Alexa Gray und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Retinal Therapies, Department of Clinical Sciences & Advanced Medicine, School of Veterinary Medicine, University of Pennsyl…. Hauptthemen laut MEDLINE: Bestrophins, Dependovirus, Genetic Vectors, Retinal Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NEI NIH HHS, National Eye Institute, Foundation Fighting Blindness.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To treat patients affected with bestrophinopathies caused by mutations in the BEST1 gene, a recombinant adeno-associated virus vector (OPGx-BEST1 or rAAV2/2-VMD2- BEST1 ) is being developed. The vector construct includes the human BEST1 cDNA under control of the VMD2/BEST1 promoter and is packaged in an AAV2 capsid. This study evaluated the efficacy and toxicity of OPGx-BEST1 administered by subretinal injection in dogs that were homozygous mutant or compound heterozygotes for 3 naturally occurring mutations in BEST1 . Twelve BEST1-mutant dogs were divided into 4 groups of 3 animals each, and they received in their left eye a subretinal injection of 0.15 mL of OPGx-BEST1 at 1 of 3 concentrations (9.5 × 10 9 vector genome [vg]/mL; 3.0 × 10 10 vg/mL; or 3.0 × 10 11 vg/mL) of OPGx-BEST1, resulting, respectively, in a low (1.4 × 10 9 vg), high (4.5 × 10 9 vg), and highest (4.5 × 10 10 vg) dose or vehicle control. The right eyes were not injected. Subretinal injections were well tolerated and were not associated with any systemic or ocular toxicity. Electroretinography showed improved rod- and cone-mediated responses in eyes treated with OPGx-BEST1. Noninvasive retinal imaging by optical coherence tomography showed improved structural integrity with a reduction or prevention of appearance of vitelliform lesions and reversal of microdetachments in the retinal areas treated with OPGx-BEST1. These results support the use of OPGx-BEST1 in clinical studies with patients affected with bestrophinopathies and define the no-observed-adverse-effect level at 4.5 × 10 10 vg/eye (0.15 mL, 3.0 × 10 11 vg/mL).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BestrophinsDependovirusGenetic VectorsRetinal DiseasesGenetic TherapyEye Diseases, HereditaryAnimalsDogsHumansDisease Models, AnimalGene Therapy AgentsRetinaElectroretinographyMutation

Stichwörter der Autor:innen

IND-enabling studyautosomal recessive bestrophinopathy (ARB)best vitelliform macular dystrophy (BVMD)gene therapyphotoreceptor function

Substanzen

BestrophinsBEST1 protein, human

Autor:innen und Institutionen

  • Division of Experimental Retinal Therapies, Department of Clinical Sciences & Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Comparative Pathology Core, Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Opus Genetics, Inc., Durham, North Carolina, USA.
  • Center for Hereditary Retinal Degenerations, Department of Ophthalmology, Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Yu Sato, William A Beltran

Förderung

  • NEI NIH HHS
  • National Eye Institute
  • Foundation Fighting Blindness
  • OPUS Genetics Inc
  • Iveric Bio Inc.

Zitieren

APA

Gray, A., Kwok, J. C., Sato, Y., Assenmacher, C. A., Choudhary, M., Jayagopal, A., Hua, P., Ying, G. S., Swider, M., Sumaroka, A., Cideciyan, A. V., Gustavo, A. D., & Beltran, W. A. (2026). Evaluation of the Toxicity and Efficacy of an Adeno-Associated Viral Vector Expressing BEST1 Delivered by Subretinal Injection in a Canine Model of Human Bestrophinopathy. Human Gene Therapy. https://doi.org/10.1177/10430342261458076

Vancouver

Gray A, Kwok JC, Sato Y, Assenmacher CA, Choudhary M, Jayagopal A, et al. Evaluation of the Toxicity and Efficacy of an Adeno-Associated Viral Vector Expressing BEST1 Delivered by Subretinal Injection in a Canine Model of Human Bestrophinopathy. Human Gene Therapy. 2026. doi:10.1177/10430342261458076

BibTeX
@article{Gray2026,
  author = {Gray, Alexa and Kwok, Jennifer C and Sato, Yu and Assenmacher, Charles-Antoine and Choudhary, Mayur and Jayagopal, Ash and Hua, Peiying and Ying, Gui-Shuang and Swider, Malgorzata and Sumaroka, Alexander and Cideciyan, Artur V and Gustavo, Aguirre D and Beltran, William A},
  title = {Evaluation of the Toxicity and Efficacy of an Adeno-Associated Viral Vector Expressing BEST1 Delivered by Subretinal Injection in a Canine Model of Human Bestrophinopathy},
  journal = {Human Gene Therapy},
  year = {2026},
  doi = {10.1177/10430342261458076}
}
Kostenlos starten →